IRD — Opus Genetics, Inc. stock price, charts and financials

QT78Opus Genetics, Inc.

Opus Genetics, Inc. (NASDAQ: IRD) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
3.73
+0.07+1.78%
OverviewShort InterestFilings
IRDQT78Opus Genetics, Inc.·NASDAQ
3.73+1.78%
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
AUPH-2.33%$15.48MESO+4.96%$16.73ZBIO-1.46%$31.96GHRS-2.07%$29.64TSHA-0.69%$6.51STOK-1.46%$32.23ABCL+31.03%$9.08VRDN-2.29%$23.05
Snapshot
Index-P/E-EPS (ttm)-1.31Insider Own21.39%Shs Outstand82.57MPerf Week-1.35%
Market Cap302.19MForward P/E-EPS next Y-0.75Insider Trans-10.21%Shs Float34.98MPerf Month-8.96%
Enterprise Value248.31MPEG0.07EPS next Q-Inst Own-Short Float12.43%Perf Quarter-31.72%
Income-93.04MP/S30.66EPS this Y13.11%Inst Trans-Short Ratio10.36Perf Half Y41.86%
Sales9.86MP/B-EPS next Y33.94%ROA-115.75%Short Interest10.27MPerf YTD82.09%
Book/sh-P/C-EPS next 5Y-ROE1147.63%52W High5.91 -37.01%Perf Year232.73%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-59.29%52W Low1.06 251.92%Perf 3Y-
Dividend Est.-EV/EBITDA-Sales past 3/5Y-29.53% -Gross Margin99.87%Volatility6.60% 6.98%Perf 5Y-
Dividend TTM-EV/Sales25.19EPS Y/Y TTM39.07%Oper. Margin-513.47%ATR (14)0.26Perf 10Y-
Dividend Ex-Date-Quick Ratio12.19Sales Y/Y TTM9.09%Profit Margin-1091.82%RSI (14)50.52Recom2.00
Dividend Gr. 3/5Y-Current Ratio12.19EPS Q/Q-212.50%SMA206.32%Beta1.21Target Price9.00
Payout0.00%Debt/Eq-Sales Q/Q-50.00%SMA50-4.00%Rel Volume0.91Prev Close3.66
Employees28LT Debt/Eq-0.57EarningsNov 17SMA2004.55%Avg Volume1.01MPrice3.73
IPO DateJan 19, 2015Option/ShortYes / YesEPS/Sales Surpr.-458.99% -26.33%Net Debt/EBITDA0.51Volume915,127Change1.78%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-07-26ReiteratedRBC Capital$10 → $9.00
Jun-23-26InitiatedRBC CapitalOutperform$10
Jun-17-26ReiteratedHC Wainwright & Co.Buy$8.00
May-21-26InitiatedLeerinkOutperform$10
Mar-11-26ReiteratedCraig-Hallum$9.00
Jan-20-26InitiatedBTIGBuy$7.00
Nov-25-25InitiatedPiper SandlerOverweight$7.00
Latest News
Aug-06-26
Aug-06-2609:21AM
Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimateszacks.com
Aug-03-26
Aug-03-2607:06AM
Opus Genetics Says Last Patient Enrolled In Registrational Phase 3 Clinical Trial Evaluating OPGx-LCA5, Investigational Gene Therapy For LCA5-Associated Inherited Retinal DiseaseBenzinga
07:00AM
Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Diseaseglobenewswire.com
Jul-29-26
Jul-29-2610:29AM
TD Cowen Initiates Coverage On Opus Genetics with Buy RatingBenzinga
Jul-20-26
Jul-20-2606:03AM
Top 3 Health Care Stocks That May Rocket Higher In JulyBenzinga
Jul-09-26
Jul-09-2607:06AM
Opus Genetics Expects To Announce Three-month Topline Data From Cohort 1 Of Phase 1/2 Trial Of OPGx-BEST1 For Best Vitelliform Macular Dystrophy Or Autosomal-recessive Bestrophinopath, During The Second Week Of September 2026Benzinga
07:00AM
Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Resultsglobenewswire.com
Jul-06-26
Jul-06-2607:00AM
Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Diseaseglobenewswire.com
Jun-26-26
Jun-26-2609:17AM
Opus Genetics Set To Join Russell 3000, 2000, Microcap Indexes, Effective June 29Benzinga
Jun-18-26
Jun-18-2612:31PM
Chardan Capital Maintains Buy on Opus Genetics, Raises Price Target to $13Benzinga
Jun-17-26
Jun-17-2608:04AM
HC Wainwright & Co. Reiterates Buy on Opus Genetics, Maintains $8 Price TargetBenzinga
05:52AM
Opus Genetics, Inc. (IRD) Discusses Early-Stage Gene Therapy Programs and Clinical Strategies for Inherited Retinal Diseases TranscriptSeekingAlpha
Jun-16-26
Jun-16-2604:33PM
Opus Genetics, Inc. (IRD) Discusses Early-Stage Gene Therapy Programs and Clinical Strategies for Inherited Retinal Diseases - SlideshowSeekingAlpha
Jun-15-26
Jun-15-2609:57AM
Citizens Reiterates Market Outperform on Opus Genetics, Maintains $11 Price TargetBenzinga
Company

Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
Total Revenue101411—————
Cost of Goods Sold Incl. D&A
000—————
Gross Profit101411—————
Selling, General and Administrative Excl. Other222218—————
Research and Development383127—————
Other Operating Expense0028—————
Operating Income-49-39-62—————
Interest Expense310—————
Unusual Expense
————————
Non-Operating Income (Expense)-55-105—————
Net Income Before Taxes-108-50-58—————
Income Taxes
000—————
Consolidated Net Income-108-50-58—————
Net Income From Continuing Operations-108-50-58—————
Net Income-108-50-58—————
EPS (Recurring)-1.27-0.80-2.15—————
EPS (Basic, Before Extraordinaries)-1.27-0.80-2.15—————
EPS (Diluted)-1.33-0.80-2.15—————
EBITDA-105-48-58—————
Other After Tax Adjustments
————————
Stock Option Compensation Expense
————————
Price To Earnings Ratio
————————
Price To Sales Ratio35.3989.302.92—————
Gross Margin100.00100.00100.00—————
Operating Margin-490.00-278.57-563.64—————
Net Margin-1,080.00-357.14-527.27—————
Shares Outstanding9562227—————
Market Capitalization3541,25032—————
Operating Lease Expense
————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$6.48$4.90$3.33$1.75$0.18● Close Price0.00M2.15M4.30M6.45M8.60MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
YERXA BENJAMIN RPresidentJul 23 '26Sale2.977,42922,064704,106Jul 27
Magrath GeorgeChief Executive OfficerJul 23 '26Sale2.959,47527,9261,731,869Jul 27
Gagnon Robert E.Chief Financial OfficerJul 23 '26Sale2.957,78322,942584,375Jul 27
SCHACHLE JOSEPH KChief Operating OfficerJul 23 '26Sale2.944,64413,653291,440Jul 27
Foundation Fighting Blindness Retinal Degeneration Funddirector, other: See RemarksMay 18 '26Sale4.351,700,0007,395,0003,792,171May 20
Gagnon Robert E.Chief Financial OfficerApr 23 '26Sale5.187,84240,658592,158Apr 27
SCHACHLE JOSEPH KChief Operating OfficerApr 23 '26Sale5.224,69724,519296,084Apr 27
YERXA BENJAMIN RPresidentApr 23 '26Sale5.247,47039,121711,535Apr 27
Magrath GeorgeChief Executive OfficerApr 23 '26Sale5.229,51149,6471,741,344Apr 27
Jayagopal AshwathChief Scientific & Dev. Ofc.Apr 23 '26Sale5.197,54239,156509,233Apr 27
Zaremba Rabourn AmyHead of Fin. Quality AssuranceApr 23 '26Sale5.201,6418,540188,671Apr 27
SCHACHLE JOSEPH KChief Operating OfficerMar 16 '26Sale5.253,71919,525300,781Mar 18
Zaremba Rabourn AmyHead of Fin. Quality AssuranceMar 16 '26Sale5.252,81614,770190,312Mar 18
Magrath GeorgeChief Executive OfficerMar 16 '26Sale5.2124,438127,3271,750,855Mar 18
Jayagopal AshwathChief Scientific & Dev. Ofc.Mar 16 '26Sale5.123,71919,046516,775Mar 18
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.